Drugs / IN-115314
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | — | immunodeficiency 11b with atopic dermatitis | 2026-06-01 | “IN-115314, an orally-administered, novel treatment for atopic dermatitis in animals (dogs), and submitted an application for marketing authorization.” inno-n.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07073677 | Jul 2025 → Sep 2026 overdue | atopic eczema | HK inno.N Corporation | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | HK inno.N Corporation | Results HK inno.N, Secures Phase 3 Success for Korea’s Only Novel JAK-1i for Canine Atopic Dermatitis inno-n.com ↗
HK inno.Nannounced on 1 June that it successfully completed a phase 3 trial of IN-115314, an orally-administered, novel treatment for atopic dermatitis in animals (dogs), and submitted an application for marketing authorization. |
| 2025-09-22 | HK inno.N Corporation | Results HK inno.N Presents Phase 1 Results for Atopic Dermatitis Drug at EADV 2025 inno-n.com ↗
In this study, the Eczema Area and Severity Index (EASI) scores decreased by up to 77.8% at 4 weeks of IN-115314 ointment application, with systemic exposure being only 1/20 of that of competing drugs, demonstrating both efficacy and safety. |
| 2025-05-28 | HK inno.N Corporation | Regulatory HK inno.N’s Investigational New Drug for Atopic Dermatitis in Companion Animals Enters Phase 3 inno-n.com ↗
On May 28, HK inno.N announced that its atopic dermatitis treatment for companion animals, IN-115314, has received approval for a Phase 3 clinical trial under an Investigational New Drug (IND) application from the Animal and Plant Quarantine Agency. |
| 2025-03-17 | HK inno.N Corporation | Regulatory HK inno.N secures MFDS approval for phase 2 clinical trial of the new JAK inhibitor inno-n.com ↗
HK inno.N announced on Monday (17th of February) that IN-115314, its new JAK inhibitor for autoimmune diseases, obtained an approval from the Ministry of Food and Drug Safety (MFDS) on the investigational new drug (IND) for phase 2 trial. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | HK inno.N Corporation | HK inno.N, Secures Phase 3 Success for Korea’s Only Novel JAK-1i for Canine Atopic Dermatitis inno-n.com ↗ |
| 2025-09-22 | HK inno.N Corporation | HK inno.N Presents Phase 1 Results for Atopic Dermatitis Drug at EADV 2025 inno-n.com ↗ |
| 2025-05-28 | HK inno.N Corporation | HK inno.N’s Investigational New Drug for Atopic Dermatitis in Companion Animals Enters Phase 3 inno-n.com ↗ |
| 2025-03-17 | HK inno.N Corporation | HK inno.N secures MFDS approval for phase 2 clinical trial of the new JAK inhibitor inno-n.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN-115314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07073677 ↗ |